Compare Amplitude Inc (AMPL) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplitude Inc vs Biogen Inc — how do they compare? Amplitude Inc trades at $12.38 (market cap $1.59B), while Biogen Inc trades at $206.76 (market cap $30.13B). The key difference: Biogen Inc is far larger — about 18.9× Amplitude Inc's market cap. Which is the better fit depends on your goals.
| AMPL | BIIB | |
|---|---|---|
Market Cap | $1.59B | $30.13B |
Sector | Technology | Health |
52-Week High | $12.69 | $216.63 |
52-Week Low | $5.61 | $128.93 |
Enterprise Value | $1.45B | $37.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amplitude (AMPL) trades at $12.19, up 8.26% over 24 hours, with strong technical momentum indicated by bullish moving averages. The company shows robust revenue growth, reaching $343.21 million in 2025, but continues to report net losses with a -26.59% margin. Recent news highlights AI-driven growth initiatives and enterprise customer expansion as key catalysts.
While analyst consensus remains bullish with 67% buy ratings and a $12.08 price target, persistent profitability challenges and ongoing legal investigations present significant risks. The stock's current valuation at 4.49x sales appears reasonable given growth prospects, but sustained losses require careful monitoring of margin improvement efforts.
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amplitude Inc
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
